Lawstreet Journal

"Why not Consider Compulsory Licensing for COVID Drugs like Remdesivir, Tocilizumab?": Supreme Court asks the Central Government

Lawstreet Journal 3 May 2021 8:22pm

Image courtesy: Lawstreet Journal Judiciary "Why not Consider Compulsory Licensing for COVID Drugs like Remdesivir, Tocilizumab?": Supreme Court asks the Central Government

On Friday, the Central Government was questioned by the Supreme Court as to why it was not considering invoking the Patents Act's powers for compulsory licensing or government-authorized use of drugs such as Remdesivir, Tocilizumab, and Favipiravar, which are used to treat COVID-19 patients.

While hearing the suo moto case on COVID-19 issues, a bench comprised of Justices DY Chandrachud, L Nageswara Rao, and S Ravindra Bhat raised the question (In Re Distribution of Essential Supplies and Services During Pandemic).

"Has the Centre considered invoking Section 92 of the Patents Act and issuing mandatory licences so that drugs can be manufactured while royalties are sorted?", Tushar Mehta, Solicitor General, was questioned by the bench.

The Centre was requested by the Bench to explain why the Court should not issue orders invoking Sections 92 or Section 100 of the Patents Act to allow the manufacture of generic drugs in the case of Remdesivir, Tolicizumab, and other drugs.

Section 92 of the Patents Act is a special provision. In the event of the public health emergency, this section allows the Central Government to issue mandatory licences for the manufacture of patented drugs. Section 100 of the Patents Act allows the Central Government to use patented inventions for government purposes.

During the hearing, Justice Ravindra Bhat stated that, "This is a perfect example of when we should impose mandatory licensing...This is a Public Health Emergency.

Justice  Ravindra Bhat also noted that India was at the forefront of the TRIPS negotiations regarding compulsory licensing provisions, and that the current situation… Continue Reading...


Tagged: Corona Updates  
Disclaimer: SoOLEGAL in Media collaboration with Lawstreet Journal. SoOLEGAL take no responsbility for the content provided by Lawstreet Journal. For any discrepancies Contact Lawstreet Journal.
Did you find this write up useful? YES 0 NO 0
Edward Dillinger   4 May 2021 2:44am
Am short of words for the amazing profit you helped me earn in just a week with binary options strategy am so sorry I doubted at the beginning, I invested read more
Reply
×

C2RMTo Know More

Something Awesome Is In The Work

0

DAYS

0

HOURS

0

MINUTES

0

SECONDS

Sign-up and we will notify you of our launch.
We’ll also give some discount for your effort :)

* We won’t use your email for spam, just to notify you of our launch.
×

SAARTHTo Know More

Launching Soon : SAARTH, your complete client, case, practise & document management SAAS application with direct client chat feature.

If you want to know more give us a Call at :+91 98109 29455 or Mail info@soolegal.com